Family · Pharmaceutical analytical standards
Palonosetron
A serotonin 5-HT3 receptor antagonist, approved in the United States in 2003 to prevent nausea and vomiting caused by chemotherapy, including the delayed phase in the following days. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.
Did you know?Its half-life is about 40 hours, very long for its class, and in about one patient in ten it exceeds 100 hours: a single administration thus also covers the days after treatment.
No product matches your search.
EDQM standards 4
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
